Gene · 134
ADORA1: adenosine A1 receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADORA1: adenosine A1 receptor. Genes, record 134. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/134
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P30542 | Adenosine receptor A1 | 326 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents88
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026062654 A | 2026-04-10 | 17 | P30542 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36613 | P30542 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36614 | P30542 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36616 | P30542 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 327 | P30542 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 327 | P30542 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 2669 | P30542 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 2670 | P30542 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 2672 | P30542 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 24223 | P30542 | Espacenet |
1 to 10 of 88
See all 88 patentsDrugs26
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ADENOSINE | CHEMBL477 | Adenosine receptor agonist | AGONIST | ChEMBL |
| AMINOPHYLLINE | CHEMBL1370561 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| AMP579 | CHEMBL3545163 | Adenosine A1 receptor agonist | AGONIST | ChEMBL |
| BAY1067197 | CHEMBL5314392 | Adenosine A1 receptor agonist | AGONIST | ChEMBL |
| CAFFEINE | CHEMBL113 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| CAFFEINE CITRATE | CHEMBL1200569 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| CAPADENOSON | CHEMBL3235279 | Adenosine A1 receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| DEFIBROTIDE | CHEMBL2108396 | Adenosine A1 receptor agonist | AGONIST | ChEMBL |
| DERENOFYLLINE | CHEMBL592435 | Adenosine A1 receptor antagonist | ANTAGONIST | ChEMBL |
| FK453 | CHEMBL440115 | Adenosine A1 receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 26
See all 26 drugsTrials187
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07469852 | CAFFEINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07466732 | CAFFEINE | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07456670 | CAFFEINE | PHASE2 | ClinicalTrials.gov | |
| NCT07348510 | AMINOPHYLLINE | ClinicalTrials.gov | ||
| NCT07262060 | CAFFEINE CITRATE | PHASE2 | ClinicalTrials.gov | |
| NCT07216365 | CAFFEINE CITRATE | PHASE2 | ClinicalTrials.gov | |
| NCT07086560 | ADENOSINE | ClinicalTrials.gov | ||
| NCT06972849 | CAFFEINE CITRATE | ClinicalTrials.gov | ||
| NCT06972108 | CAFFEINE CITRATE | PHASE2 | ClinicalTrials.gov | |
| NCT06855108 | CAFFEINE CITRATE | PHASE3 | ClinicalTrials.gov |
1 to 10 of 187
See all 187 trialsNIH grants1,396
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADORA1 papers | Newest fiscal year |
|---|---|---|---|
| ZIADA000493 | Functional and Pharmacological Significance of Receptor Heteromers in the CNS | 12 | 2025 |
| ZIADK031117 | Development of Drugs Acting at Adenosine Receptors | 10 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 4 | 2025 |
| P20GM103395 | Alaska INBRE 5 One Health | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30DK056338 | Texas Medical Center Digestive Diseases Center | 3 | 2025 |
| R01HL135109 | Targeting the Arrhythmogenic Sources of Human Atrial Fibrillation | 3 | 2025 |
| R01NS034773 | ISCHEMIC PRECONDITIONING: MECHANISMS OF NEUROPROTECTION | 3 | 2025 |
| R01NS127846 | Therapies for Epilepsy Prevention - Focus on Adenosine | 3 | 2025 |
| R35GM128641 | Structure, pharmacology and signaling of G protein-coupled receptors (GPCRs) in inflammation | 3 | 2025 |
1 to 10 of 1,396Source NIH's project files
See all 1,396 nih grantsPapers2,244
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ADORA1 inhibition suppresses colon cancer development via hippo tumor suppressor pathway. | Cell Death Differ | 2026 | 42763325 | PubTator, text mining | PubMed |
| From phenotypic screening to target and compound prioritization for autosomal dominant polycystic kidney disease. | SLAS Discov | 2026 | 42744122 | PubTator, text mining | PubMed |
| Increased ADORA1 expression in pancreatic islets coincides with insulin secretory defects in human type 2 diabetes. | J Biol Chem | 2026 | 42660457 | PubTator, text mining | PubMed |
| Integrating single-cell transcriptomics and network pharmacology identifies ADORA1 as a candidate receptor for gastrodin derivatives in lung adenocarcinoma. | Biomed Pharmacother | 2026 | 42659805 | PubTator, text mining | PubMed |
| Targeting ERO1A Enhances Antitumor Immune Response by Recruiting CD8+ T Cells and Synergizing with PD-L1 Blockade in Liver Cancer. | Cancer Immunol Res | 2026 | 42644613 | PubTator, text mining | PubMed |
| Enterochromaffin cells as a cellular integration hub for cooperative microbial signaling to modulate gut serotonin and motility. | Proc Natl Acad Sci U S A | 2026 | 42636369 | PubTator, text mining | PubMed |
| Anticonvulsant effects, safety, and sex-dependent molecular signatures of cannabidiol treatment in a preclinical model of audiogenic epilepsy. | Front Pharmacol | 2026 | 42630256 | PubTator, text mining | PubMed |
| Delta-Band Dynamics of CaMKI-Positive Preoptic Neurons Encode Thermal Homeostatic Information. | Neurosci Bull | 2026 | 42587252 | PubTator, text mining | PubMed |
| Potential Gastric Cancer Biomarker in Gastric Juice: Adenosine and Its Role in the Immune Evasion Mechanism of Gastric Cancer. | J Interferon Cytokine Res | 2026 | 42455003 | PubTator, text mining | PubMed |
| Synthesis of novel 1,2,4-oxadiazole-isoxazoline hybrids and their in silico potential with adenosine receptors. | Beilstein J Org Chem | 2026 | 42445721 | PubTator, text mining | PubMed |
1 to 10 of 2,244
See all 2,244 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/134
GET https://conductscience.org/api/genes/v1/134/patents?page=2